Actinium Pharmaceuticals, Inc. (ATNM)

Targeted Therapies for Patients with Unmet Needs

Actinium is developing a pipeline Antibody Radiation Conjugates for targeted conditioning and combination therapies

February 7, 2019 KOL Event

Dr. Sergio Giralt Memorial Sloan Kettering Cancer Center

Targeted Conditioning for BMT and CAR-T with Antibody Radiation-Conjugates

The Science Behind Antibody Radiation Conjugates

Targeted Conditioning and ARC Pipeline

SIERRA: Pivotal Phase 3 Clinical Trial of Iomab-B

News

Featured Video

A Phase III Trial Evaluating Iomab-B Prior to HCT in Relapsed/Refractory AML

$A Phase III Trial Evaluating Iomab-B Prior to HCT in Relapsed/Refractory AML$

Tweets by ActiniumPharma

Investor Relations

Investor Presentation

Contact Us